Jeegar Pravinkumar Patel - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.

Role
Chief Scientific Officer
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol
EVMN on NYSE
Transactions as of
07 Nov 2025
Net transactions value
$0
Form type
4
Filing time
12 Nov 2025, 16:21:52 UTC
Previous filing
05 Nov 2025
Next filing
11 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Patel Jeegar Pravinkumar Chief Scientific Officer C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO /s/ Gregory S. Moss, Attorney-in-Fact 12 Nov 2025 0002092017

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVMN Common Stock Conversion of derivative security +3,175 +5.9% 57,091 07 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVMN Series B Preferred Stock Conversion of derivative security -25,000 -100% 0 07 Nov 2025 Common Stock 3,175 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date.